摘要
Immune checkpoint blockade therapy improved the survival rates of non-small cell lung cancer but only a proportion of patients benefit. Here authors follow the humoral and cellular immunological parameters of patients undergoing anti-PD1 therapy longitudinally and find that levels and functional properties of cytotoxic T cells, and especially CD8(+)CD101(hi)TIM3(+) cells determine the response. @@@ Response to immunotherapy widely varies among cancer patients and identification of parameters associating with favourable outcome is of great interest. Here we show longitudinal monitoring of peripheral blood samples of non-small cell lung cancer (NSCLC) patients undergoing anti-PD1 therapy by high-dimensional cytometry by time of flight (CyTOF) and Meso Scale Discovery (MSD) multi-cytokines measurements. We find that higher proportions of circulating CD8(+) and of CD8(+)CD101(hi)TIM3(+) (CCT T) subsets significantly correlate with poor clinical response to immune therapy. Consistently, CD8(+) T cells and CCT T cell frequencies remain low in most responders during the entire multi-cycle treatment regimen; and higher killer cell lectin-like receptor subfamily G, member 1 (KLRG1) expression in CCT T cells at baseline associates with prolonged progression free survival. Upon in vitro stimulation, CCT T cells of responders produce significantly higher levels of cytokines, including IL-1 & beta;, IL-2, IL-8, IL-22 and MCP-1, than of non-responders. Overall, our results provide insights into the longitudinal immunological landscape underpinning favourable response to immune checkpoint blockade therapy in lung cancer patients.
学科与关键词
- Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitorHe, L-N; Fu, S.; Ma, H.; Chen, C.; Zhang, X.; Li, H.; Du, W.; Chen, T.; Jiang, Y.; Wang, Y.; Wang, Y.; Zhou, Y.; Lin, Z.; Yang, Y.; Huang, Y.; Zhao, H.; Fang, W.; Zhang, H.*; Zhang, L.*; Hong, S.*ESMO Open, 2022, 7(6).
- Low Infiltration of CD8+PD-L1+T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung CarcinomaLi, Liuning; Lu, Guojie; Liu, Yang; Gong, Longlong; Zheng, Xue; Zheng, Hongbo; Gu, Weiguang*; Yang, LinFrontiers in Oncology, 2021, 11: 658690.被引 12
- The primordial differentiation of tumor-specific memory CD8+T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodesHuang, Qizhao; Wu, Xia; Wang, Zhiming; Chen, Xiangyu; Wang, Lisha; Lu, Yijun; Xiong, Dan; Liu, Qiao; Tian, Yuhan; Lin, Huayu; Guo, Junyi; Wen, Shuqiong; Dong, Wei; Yang, Xiaofan; Yuan, Yuchen; Yue, Zhengliang; Lei, Shun; Wu, Qing; Ran, Ling; Xie, Luoyingzi; Wang, Yifei; Gao, Leiqiong; Tian, Qin; Zhou, Xinyuan; Sun, Beicheng*; Xu, Lifan*; Tang, Zhonghui*; Ye, Lilin*Cell, 2022, 185(22): 4049-+.被引 61
